← Back to Search

Procedure

Invasive Strategy (INV) for Myocardial Ischemia (ISCHEMIA Trial)

N/A
Waitlist Available
Led By David J Maron, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3.2 year follow-up (median)
Awards & highlights

ISCHEMIA Trial Summary

This trial is testing whether an initial invasive strategy of cardiac catheterization followed by optimal revascularization, if feasible, in addition to OMT, will reduce cardiovascular death, nonfatal myocardial infarction, resuscitated cardiac arrest, or hospitalization for unstable angina or heart failure in participants with SIHD and moderate or severe ischemia over an average follow-up of approximately 3.5 years compared with an initial conservative strategy of OMT alone with catheterization reserved for failure of OMT.

Eligible Conditions
  • Myocardial Ischemia
  • Heart Disease
  • Coronary Heart Disease
  • Cardiovascular Disease
  • Coronary Artery Disease

ISCHEMIA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3.2 year follow-up (median)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3.2 year follow-up (median) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cumulative Event Rate of Death From Any Cause
Cumulative Event Rate of Death From Cardiovascular Causes or Myocardial Infarction
Cumulative Event Rate of Myocardial Infarction
+9 more

ISCHEMIA Trial Design

2Treatment groups
Active Control
Group I: Invasive Strategy (INV)Active Control5 Interventions
Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
Group II: Conservative StrategyActive Control2 Interventions
Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.

Find a Location

Who is running the clinical trial?

Emory UniversityOTHER
1,636 Previous Clinical Trials
2,555,394 Total Patients Enrolled
10 Trials studying Myocardial Ischemia
4,490 Patients Enrolled for Myocardial Ischemia
Massachusetts General HospitalOTHER
2,928 Previous Clinical Trials
13,193,176 Total Patients Enrolled
12 Trials studying Myocardial Ischemia
2,090 Patients Enrolled for Myocardial Ischemia
Montreal Heart InstituteOTHER
120 Previous Clinical Trials
63,640 Total Patients Enrolled
13 Trials studying Myocardial Ischemia
3,334 Patients Enrolled for Myocardial Ischemia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people currently being signed up to participate in this clinical trial?

"The clinical trial mentioned is no longer enrolling patients, however there are over 1500 other trials that are still recruiting."

Answered by AI

Where are patients being recruited for this trial?

"This trial has 100 locations, which include Spectrum Health in Grand Rapids, Miriam Hospital in Providence, and University of Alberta in Edmonton."

Answered by AI
Recent research and studies
American Heart JournalJournal
Is Cardiac Catheterization Necessary Before Initial Management of Patients with Stable Ischemic Heart Disease? Results from a Web-based Survey of Cardiologists
Maron, David J., Gregg W. Stone, Daniel S. Berman, G. B. John Mancini, Theresa A. Scott, Daniel W. Byrne, Frank E. Harrell Jr, et al.. 2011. “Is Cardiac Catheterization Necessary Before Initial Management of Patients with Stable Ischemic Heart Disease? Results from a Web-based Survey of Cardiologists”. American Heart Journal. Elsevier BV. doi:10.1016/j.ahj.2011.09.001.
Journal of Nuclear CardiologyJournal
Lessons Learned from MPI and Physiologic Testing in Randomized Trials of Stable Ischemic Heart Disease: COURAGE, BARI 2D, FAME, and ISCHEMIA
Phillips, Lawrence M., Rory Hachamovitch, Daniel S. Berman, Ami E. Iskandrian, James K. Min, Michael H. Picard, Raymond Y. Kwong, et al.. 2013. “Lessons Learned from MPI and Physiologic Testing in Randomized Trials of Stable Ischemic Heart Disease: COURAGE, BARI 2D, FAME, and ISCHEMIA”. Journal of Nuclear Cardiology. Springer Science and Business Media LLC. doi:10.1007/s12350-013-9773-4.
American Heart JournalJournal
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial: Rationale and Design
Maron, David J., Judith S. Hochman, Sean M. O’Brien, Harmony R. Reynolds, William E. Boden, Gregg W. Stone, Sripal Bangalore, et al.. 2018. “International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial: Rationale and Design”. American Heart Journal. Elsevier BV. doi:10.1016/j.ahj.2018.04.011.
JAMA CardiologyJournal
Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial
Hochman, Judith S., Harmony R. Reynolds, Sripal Bangalore, Sean M. O’Brien, Karen P. Alexander, Roxy Senior, William E. Boden, et al.. 2019. “Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial”. JAMA Cardiology. American Medical Association (AMA). doi:10.1001/jamacardio.2019.0014.
~406 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top